Form 4: Eli Lilly Executive Sells Shares Under Pre-Arranged Trading Plan

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 750 shares of common stock at $950 per share on August 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Donald A. Zakrowski, a Senior Vice President at Eli Lilly, sold 750 shares of the company's common stock on August 26, 2024.
• The sale was executed at a price of $950 per share.
• This transaction was conducted under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which was adopted on November 16, 2023.
• Following the transaction, Mr. Zakrowski directly owns 6,380 shares of Eli Lilly common stock.
• He also indirectly owns 1,712 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Positives

• The sale was conducted under a pre-arranged trading plan, which is a common practice for executives to avoid accusations of insider trading.

Risks

• While the sale was under a pre-arranged plan, large sales by executives can sometimes be perceived negatively by the market.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often conducted under pre-arranged trading plans to comply with insider trading regulations. This transaction is not unusual and is part of normal executive compensation and financial planning.

Comparison to Industry Standards

• Many executives at publicly traded companies use 10b5-1 trading plans to manage their stock holdings.
• The sale by Mr. Zakrowski is similar to transactions by executives at comparable pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ), where pre-planned sales are common.
• These plans allow executives to sell shares without the appearance of trading on inside information.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

insider trading, Rule 10b5-1, stock sale, executive, share transaction, Eli Lilly, LLY